Background: The bidirectional interaction between melatonin and the immune system has largely gone unexplored in a clinical context and especially in a psychiatric population. This study explored the association between melatonin during the day and inflammatory cytokines in young adult patients seeking psychiatric care. Methods: Samples and data were collected from 108 young adults (mean age 21, SD = 2) at an outpatient clinic for affective disorders. Daytime saliva melatonin levels were analyzed with enzyme-linked immunosorbent assay (ELISA) in relation to normalized serum expression levels of 72 inflammatory markers in a proximity extension assay (PEA). In a post hoc analysis the markers associated with melatonin were tested in a generalized linear model to see whether there is a relationship to anxiety disorder or depression. Results: After Bonferroni correction for multiple testing, melatonin levels at 11:00 were positively correlated with CD5 (p = 4.2e-4). Melatonin levels after lunch were correlated with CCL2/MCP-1 (p = 4.2e-4), CCL3/MPI-1α (p = 6.5e-4) and VEGF-A (p = 5.3e-6). In the generalized linear model, positive associations were found for the presence of any anxiety disorder with melatonin after lunch (p = 0.046), VEGF-A (p = 0.001) and CCL3/ MPI-1α (p = 0.001). Conclusion: Daytime saliva levels of melatonin were related to several inflammatory markers in young adults with psychiatric disorders. This observation likely reflects the bidirectional relationship between melatonin production and the immune system. These findings may have relevance for the understanding of psychiatric disorders and other conditions associated with low-grade inflammation. (J.L. Cunningham).
Introduction
The circadian release of melatonin from the pineal gland helps to regulate the rhythm of bodily functions hierarchically synchronized by the suprachiasmatic nucleus (Buhr and Takahashi, 2013) . Melatonin is additionally produced by all mitochondria-containing cells in a noncircadian manner and exerts a wide diversity of autocrine and paracrine effects (Acuna-Castroviejo et al., 2014) . Arguably, melatonin's most important function is as an antioxidant protecting cells from oxidative damage (Manchester et al., 2015) .
A complex and fascinating interaction between melatonin and the immune system that extends well beyond antioxidative effects is summarized in a recent review (Hardeland, 2018) . Melatonin is most known for its anti-inflammatory properties; however, depending on various conditions, including cell types, level and duration of inflammation, melatonin can have proinflammatory effects (Hardeland, 2018) . Proinflammatory actions of melatonin enhance the resistance against pathogens but may be detrimental in autoimmune diseases (such as rheumatoid arthritis) (Galbo and Kall, 2016) . The anti-inflammatory actions of melatonin are of particular interest, however, because they are observed in high-grade inflammation (e.g., sepsis, ischemia/reperfusion and brain injury) and also in chronic low-grade inflammation during aging and in neurodegenerative diseases, with suggested relevance also in mood disorders (Hardeland, 2018) . The role of melatonin in mood disorders has been researched (Anderson, 2017) but the connection between daytime melatonin and inflammation in mood disorders remains to be fully elucidated.
The immune system is under circadian control, which is reflected in many ways. For instance, immune cell response to antigen exposure is modulated by central circadian mediators and differs depending on the time of day (Guerrero-Vargas et al., 2014; Rahman et al., 2015) . There is an endogenous circadian regulation of inflammatory cytokines such as C-X-C motif chemokine ligand 8 (CXCL8)/interleukin 8 (IL-8) and C-C motif chemokine ligand 2 (CCL2)/monocyte chemoattractant protein-1 (MCP-1) in the presence of bacterial lipopolysaccharide (LPS) in humans (Rahman et al., 2015) . Intravenous administration of melatonin suppresses markers of inflammation and oxidative damage in a human daytime endotoxemia model but these effects are dependent on the time of administration (Alamili et al., 2014) . Suprachiasmatic nucleus lesion leads to a 10-fold increase in LPS-induced inflammatory cytokine release in animals (Guerrero-Vargas et al., 2014) . LPS may also be involved in chronic low-grade inflammation. Lipopolysaccharide binding protein (LBP) has been suggested as a marker for low grade inflammation related to LPS (Citronberg et al., 2016; Gonzalez-Quintela et al., 2013) . When LPS levels are high, LBP production is induced in the liver and has a long half-life in serum. As a recent example of this, LBP was found to be higher in couples in hostile marital interactions and a history a mood disorder may contribute to this association (Kiecolt-Glaser et al., 2018) .
Peripheral proinflammatory cytokines, such as tumor necrosis factor alpha (TNF)-α, shut down pineal melatonin production, contributing to the decreased pineal circadian melatonin synthesis across many medical conditions (da Silveira Cruz-Machado et al., 2012) . This regulation can be mediated by TNF-α directly in pinealocytes or indirectly via tolllike receptor-4 activation in microglia around the pineal gland, which drives local TNF-α production and release (da Silveira Cruz-Machado et al., 2010; Markus et al., 2017) . Reduction in the nocturnal melatonin surge is necessary to allow leukocyte migration to sites of injury in that circulating melatonin regulates endothelial tight junctions restricting leukocyte migration to sites of injury (Man et al., 2016) .
During immunological challenge, immune cells are influenced by both autocrine and paracrine melatonin. While immune activation reduces melatonin production by pinealocytes, the production of melatonin is upgraded peripherally given that activated macrophages/microglia synthesize melatonin in a nuclear factor kappaB (NF-κB)dependent manner at the site of the inflammatory response (Markus et al., 2017) . In cultured macrophages, NF-κB signaling pathways induce the transcription of the arylalkylamine N-acetyltransferase (AA-NAT) gene needed to catalyze the N-acetylation of serotonin into melatonin (Muxel et al., 2012) . In turn, melatonin enhances phagocytosis through autocrine action and Luzindole, a competitive antagonist of melatonin receptors, decreases macrophage phagocytic activity (Muxel et al., 2012) . This bidirectional relationship between melatonin and the immune system has been termed the immune-pineal axis (Markus et al., 2017) .
Few studies have investigated potential associations between endogenous daytime levels of melatonin and cytokine levels in clinical settings. Morning serum levels of melatonin were lower and TNF-α higher when patients with newly diagnosed multiple sclerosis were compared with healthy controls, but not significantly correlated with each other (Farhadi et al., 2014) . In patients with chronic renal failure, melatonin levels were lower both day and night and inversely correlated with TNF-α (Pinto et al., 2016) . In contrast, patients with polymyalgia rheumatica had higher levels of melatonin compared with controls, with the relative difference being most pronounced during the day (Galbo and Kall, 2016) . These studies indicate an interaction between melatonin and serum inflammatory markers but the studies differ in sampling times, which may explain some of the discrepancies.
Disruption in endocrine and inflammatory response systems are pathophysiological mechanisms implicated in the etiology of depression, anxiety and sleep disorders (Haapakoski et al., 2016; Leighton et al., 2018; Miller and Raison, 2016; Young et al., 2014) , with possible relevance for prognosis and treatment response (Jha and Trivedi, 2018; Kappelmann et al., 2016) . Previously, we have identified a negative correlation between bedtime melatonin and depressive symptoms in the present cohort of young adult patients seeking psychiatric care (Sundberg et al., 2016) . The relationship between melatonin and inflammation in psychiatric patients, however, is largely unexplored.
This study aimed to explore the interaction between daytime levels of melatonin in saliva taken at six time points and levels of a large panel of inflammatory cytokines in young adults with psychiatric morbidity. Based on data showing a correlation between depression and evening levels of melatonin in the same cohort of patients (Sundberg et al., 2016) , we hypothesized that melatonin levels in the evening would correlate with levels of inflammatory markers. A secondary hypothesis was that melatonin levels taken mid-day would correlate with inflammatory markers. In addition, we investigated the potential relationship between inflammatory markers during the day, melatonin levels and the presence of the clinical variables: depression or anxiety disorder.
Materials and methods

Ethical approval and patient consent
The study was approved by the Regional Ethics Committee in Uppsala (Dnr. 2012 /81, Dnr. 2012 /81/1 and Dnr. 2013 and all participants gave written consent to participate in the study.
Data cohort
The material and data used in this observational, cross-sectional cohort study, which has been previously described (Sundberg et al., 2016) , originate from the Uppsala Psychiatric Patient Samples (UPP) cohort. All data were collected from patients seeking care between 2012 and 2014 at an outpatient clinic for young adults of the Section for Affective Disorders at Uppsala University Hospital, Uppsala, Sweden. This outpatient clinic provides care for patients aged 18-25 years, with mainly mood and anxiety disorders but also neuropsychiatric and personality disorders. Of 722 consecutive patients, 300 agreed to participate in the UPP study. Of these, 125 completed saliva sampling. Six patients were excluded because they did not fulfill criteria for any DSM-IV Axis 1 diagnosis. For 11 patients, blood sampling was missing or incomplete. Thus, the final sample comprised 108 patients with a DSM-IV Axis 1 disorder. Saliva and blood samples for all 108 patients were included in this study. No patients were taking antidepressant medication targeting melatonin receptors MT1/MT2 (agomelatine or ramelteon).
Clinical data
Demographic characteristics of the study participants are shown in Table 1 . The procedure for assessment of psychiatric diagnoses, symptoms and physical health examination upon entering the UPP has been described in detail elsewhere (Cunningham et al., 2017) . Diagnoses are based on the structured interviews used: the Swedish version of the M.I.N.I. International Neuropsychiatric Interview (M.I.N.I. 6.0) or the Structural Clinical Interview for DSM IV axis I disorders (SCID-I). All interviews were performed by trained doctors or psychologists. Physical examination included the measurement of body mass index (BMI) using the formula BMI = kg/m2.
Melatonin analysis
Melatonin in saliva was analyzed with competitive enzyme-linked immunosorbent assay (ELISA). This procedure has been described previously (Sundberg et al., 2016) . In short, participants were instructed to collect saliva samples at six time points during the waking hours of one day: when waking up, 30 min after waking up but before breakfast, at 11.00 h, 30 min after lunch, at 22.00 h and just before going to bed. Time points were chosen to capture the rise of melatonin in the evening before sleep and variation in daytime melatonin and specifically after meals. Saliva was collected using inert polymer cylindrical swabs (10 mm × 30 mm) that were subsequently placed in a storage tube consisting of a large outer tube with a small insert and snap cap (swabs and tubes from Salimetrics Europe Ltd., Suffolk, UK) and kept in the refrigerator until delivery to the lab within 48 h. Participants were instructed not to eat or drink 30 min before sampling. The participants documented collection times. To ensure compliance the research assistant verified collection times and sampling method with the patient upon receipt (samples not collected as instructed were excluded). Of maximally 648 (6 × 108) hormone measurements, 31 (4.8 %) were missing because of mistakes in saliva sampling or insufficient saliva volume. Total assay variability was < 11 %. Upon receipt, tubes were centrifuged and stored at −20°C until analysis. Salivary melatonin was measured with competitive ELISA (Direct Salivary Melatonin Elisa EK-DSM, Bühlmann Laboratories AG, Schönenbuch. Switzerland). Analyses were performed at the routine laboratory of the Department of Clinical Chemistry at Uppsala University Hospital, Uppsala, Sweden. The laboratory is certified by a Swedish government authority (Swedac).
Proseek analysis of relative plasma levels of inflammatory proteins
Blood samples, collected during office hours, were obtained from non-fasting patients and kept in −80°C at Uppsala Biobank. The relative levels of 91 inflammatory proteins were analyzed in 108 plasma samples from the study cohort using the Proseek Multiplex Inflammation panel (Olink Bioscience, Sweden), a proximity extensionbased assay (PEA). The 91 proteins belonged to a preset inflammatory panel, initially including 92 proteins; however, one protein (Beta-nerve growth factor) was excluded by the manufacturer (see Supplementary  Table 2 ). In short, PEA technology allows amplification and quantification of antibody-coupled, proximity-dependent DNA templates, reflecting relative protein levels in the sample (Assarsson et al., 2014) . With detection sensitivity down to fg/mL, the assay can be used to compare relative protein values between groups but is not an absolute quantification. All samples were analyzed with the same batch of reagents at the Clinical Biomarker Facility at the SciLife Lab in Uppsala. DNA amplification and quantification were carried out using the Bio-Mark™ HD real-time PCR platform (Fluidigm, South San Francisco, CA, USA).
Plasma was isolated from blood samples and stored at −80°C within < 60 min after isolation. After thawing on ice for the first time, samples were transferred to 96-well plates with 90 samples and 6 controls (three inter-plate controls and three negative controls [buffer]) evenly distributed over the plates. Incubation mixes (3 μL) containing 92 pairs of unique DNA oligonucleotides each labeled to a corresponding antibody were combined with plasma samples (1 μL) and incubated at 4°C overnight. PEA enzymes and PCR reagents were added in a 96 μL extension mix, after which samples were incubated at room temperature for 5 min. The plate was then transferred to the thermal cycler to perform an initial DNA extension for 20 min at 50°C and subsequent DNA amplification in 17 cycles. Following the manufacturer's instructions, a 96.96 Dynamic Array IFC (Fluidigm, South San Francisco, CA, USA) was prepared and primed while the sample mixture (2.8 μL) was mixed with 7.2 μL detection mix in a new plate. The right side of the primed 96.96 Dynamic Array IFC was loaded with 5 μL of this mixture and the left side with the unique primer pairs for each protein. Using the instructions for Proseek, the protein expression program was then run in the Fluidigm Biomark reader.
Each sample was spiked with one detection control, one extension control and two incubation controls (green fluorescent protein and phycoerythrin). Data normalization was performed using GenEx software in the Olink Wizard. The quantification cycle (Cq) values generated in the real-time PCR were used to calculate the normalized protein expression (NPX) in three steps. First, technical variations were corrected by subtracting the extension control from the Cq value of every sample (ΔCq sample = Cq sample -Cq extension control). The interplate control was then subtracted to compensate for potential variations between runs (ΔΔCq = ΔCq sample -ΔCq inter-plate control). The NPX was finally calculated by normalization against a calculation correction factor (NPX = correction factor -ΔΔCq sample). The NPX data were presented on a Log2 scale.
The samples were analyzed together, randomly distributed across eight plates. The samples were normalized for plate differences using a median normalization, applied separately for each protein. For this normalization, we considered only the 72 proteins with detectable values in at least 50 % of all the plasma samples (see Supplementary  Table 1 ). Across all 92 assays, the mean intra-assay and inter-assay variations observed were 7 % and 18 %, respectively.
Analysis of plasma protein levels with multiplex electrochemiluminescence analysis
As a validation step, two of the plasma proteins found to be significantly associated with melatonin levels after correction for multiple analyses were quantified using an electrochemiluminescence sandwich immunoassay from the Meso Scale Discovery (Rockville, MD, USA) multiplex platform.
In brief, plasma samples were applied to a primary antibody-coated 96-well plate. After subsequent dilution, incubation and washing, the captured proteins were incubated with secondary antibodies labelled with an electrochemiluminescence tag. The plate was then inserted into a Sector Imager 2400 (MSD, Gaithersburg, MD), where a voltage applied to the plate electrodes causes the captured labels to emit light. The MSD Discovery Workbench Software was used to convert the intensity of emitted light to protein concentrations using interpolation from log calibrator curves corresponding to the protein of interest. The validation data were only available for two of the significant markers, namely CCL2/MCP-1 and vascular endothelial growth factor A (VEGF-A) (K15047D-1 and K15050D-1, MSD, Gaithersburg, MD). According to the manufacturer, the inter-assay variation for highest/lowest standards of CCL2/MCP-1 and VEGF-A has a span of (8.9-3.0) and (2.0-5.3 %), respectively. Internal standards showed an inter-assay variation of 10 %.
Further we have measured total LBP (lipopolysaccharide binding protein) as a proxy for LPS in all 108 patients using the same multiplex electrochemiluminescence analysis (K151IYC-1, MSD, Gaithersburg, MD). Our internal standards showed an inter-assay variation of 10 % or less for all three assays.
Statistical analyses
Statistical analyses were performed using the software SPSS (version 23.0) and R version 3.4.2. Results from the PEA are presented as NPX values, a relative measurement on the log2 scale. The samples were distributed over eight plates in the PEA experiment. The plate effect was removed using a median normalization based on all plasma samples analyzed together. The plate normalized NPX values were used in all analyses involving PEA data. Limit of detection (LOD) was strictly defined as three standard deviations above background. Lower limit of quantification and upper limit of quantification were defined as lowest and highest concentrations measured with %CV < 30 and relative error (RE) < 30 %. Values below the LOD were replaced by the LOD. The melatonin values were not normally distributed and therefore log10-tranformed before all analyses.
The association between protein level (NPX) and log10 (melatonin) was assessed using linear regression with the protein value (NPX) as the dependent variable and melatonin and relevant covariates as independent variables. The association adjusted for covariates was assessed using a likelihood ratio test. The covariates were sex, BMI, use of antidepressant medication and use of oral contraceptives. Of the 91 proteins on the PEA array, we excluded those with more than 50 % of the values below LOD before further analyses. There was no missing data for reasons other than low signal. Thus, 72 markers remained after this exclusion criterion was applied. Three proteins (IL-17A, IL-17C and FGF-5) with more than 20 % of the values below LOD were discretized as above LOD (1) or below LOD (0) and the analyses were performed using logistic regression instead of linear regression. All tests were corrected using the Bonferroni method with the significance level set at error α = 0.05 divided by the number of proteins used to analyze the data (72); thus, a p-value below 6.9e −4 was considered significant for the main analysis.
The relationship between melatonin values at each time point and inflammatory markers was analyzed in the whole sample. In a post hoc analysis the markers that had shown a correlation to saliva melatonin were studied in relationship to the presence of depressive episode or anxiety disorder in a generalized linear model, controlling for sex, antidepressant medication, anticonception and BMI.
Levels of inflammatory markers VEGF-A and CCL2/MCP-1 that were measured with PEA were validated using multiplex electrochemiluminescence analysis. The correlation between plate normalized NPX values from PEA and log2-transformed values (pg/ml) from the multiplex assay were assessed using Spearman's rank-order correlation.
Results
Associations between saliva melatonin levels and inflammatory markers
The associations between protein level and melatonin are summarized in heat maps using Euclidean distance and complete linkage hierarchical clustering: positive associations are shown in red and negative associations in blue (Fig. 1.) . Analyses were corrected for covariates sex, BMI, use of antidepressant medication and use of oral contraceptives. Supplementary Table 2 
presents a list of associations and p-values for all proteins.
There were no significant correlations between bedtime melatonin and inflammatory markers in the Proseek Multiplex Inflammation panel after correction for multiple testing ( Fig. 1 and Supplementary Table 2) . Thus, the primary hypothesis that melatonin levels in the evening would correlate with levels of inflammatory markers was not confirmed.
For daytime melatonin values and inflammatory markers, postprandial melatonin was positively correlated with VEGF-A (p = 5.8e-6), CCL2/MCP-1 (p = 4.2e-4) and CCL3/monocyte inflammatory protein-1α (MIP-1α) (p = 6.5e-4). Melatonin at 11:00 was positively correlated with cluster of differentiation 5 (CD5) (p = 4.2e-4). For these markers, all values were within the level of quantification and well above LOD. Adding bedtime melatonin to the respective models did not influence the associations. BMI was positively correlated to VEGF-A (p = 0.011), CCL2/MCP-1 (p = 0.001) and CCL3/MIP-1α (p = 0.028) (Spearman). The regression analysis, however, showed that the associations between melatonin and these markers of inflammation independent of BMI.
To study if the daytime/nighttime melatonin ratio, in addition to the daytime melatonin, is associated to protein level, melatonin at bedtime was added to the two models predicting protein level for 11:00 and post prandial melatonin. A model improvement would suggest that melatonin at bedtime in combination with the respective daytime levels would better predict protein level than each timepoint alone. This was, however, not the case and we can conclude that the daytime/nighttime ratio is not associated to protein level.
Post hoc analysis of the association between melatonin levels, inflammatory markers and psychiatric disorders
In the generalized linear model, melatonin at 11:00 was not associated with anxiety disorder (p = 0.73) or depression (p = 0.72). Melatonin after lunch was positively associated to the presence of any anxiety disorder (p = 0.046) and this association remained when adding depression to the model (p = 0.04). Melatonin after lunch was not associated with depression (p = 0.47). VEGF-A was associated with anxiety (p = 0.001) but not with depression (p = 0.6); the same findings occurred for CCL3/MIP-1α for anxiety (p = 0.001) and depression (p = 0.4). CCL2/MCP-1 was not linked to anxiety (p = 0.18) but negatively associated with current depression (p = 0.042). Finally, CD5 was neither associated with anxiety (p = 0.18) nor with depression (p = 0.4).
Validation of PEA data
Plate-normalized NPX values from PEA and log2-transformed meso scale values (pg/ml) were correlated with each other: VEGF-A (r = 0.56, p = 6.72e-10), CCL2/MCP-1 (r = 0.60, p = 1.83e-11).
Post hoc analysis of association between melatonin levels and inflammatory markers in women
When looking at only women (n = 94), melatonin at 11:00 am was correlated to LAP-TGFB1 (p = 9.3e-4), CD5 (p = 1.5 e-5), CD6 (p = 1e-5) and CXCL8/ IL-8 (p = 7.4e-4). Daytime post-prandial values of melatonin were correlated to IL-10RB (p = 8.2e-4), CCL3/MIP1-α (p = 2.6e-4) and VEGF-A (p = 9e-6) (see Fig. 2 ).
Analysis of association between LBP, levels of melatonin and inflammatory markers
Meso scale values of LBP (ng/ml) correlated with VEGF-A (r = 0.397, p = 7.9e-5) and CCL3/MIP-1α (r = 0.281, p < 0.00397). No associations were found for LBP with BMI, sex, medication, the diagnosis of depressive episode or any anxiety disorder (Mann Whitney). For both VEGF-A and CCL3/MIP-1α, the associations with melatonin were independent from LBP and adding LBP to the models did not influence the strength of these associations (data not shown).
Discussion
The main finding in this study is that daytime saliva levels of melatonin, but not bedtime melatonin levels as hypothesized, were related to inflammatory markers in blood in young adults with psychiatric I. Sundberg, et al. Psychoneuroendocrinology xxx (xxxx) xxxx morbidity. Specifically, after correction for multiple testing, daytime postprandial melatonin levels were associated with levels of VEGF-A, CCL2/MCP-1 and CCL3/MIP-1α and melatonin levels at 11:00 were associated with levels of CD5. Elevated postprandial levels of melatonin and cytokines (VEGF-A and CCL3/MIP-1α) were more common in patients with anxiety disorders, whereas CCL2/MCP-1 was negatively associated with depression. The results demonstrate an association between melatonin and the immune system in a clinical context of psychiatric patients. The associations between daytime melatonin levels and inflammatory markers and anxiety disorders are novel findings but find support in previous work. The three markers associated with daytime postprandial melatonin levels in this study (VEGF-A, CCL2/MCP-1 and CCL3/MIP-1α) have been linked to depression and anxiety (Gaspersz et al., 2017; Leighton et al., 2018) . Production capacity of several cytokines, including CCL2/MCP-1, was positively associated with severity of depressive and, in particular, anxiety symptoms, even while taking lifestyle and health factors into account (Vogelzangs et al., 2016) . Several studies report high peripheral VEGF-A levels in patients with depression compared with healthy controls (Carvalho et al., 2015; Sharma et al., 2016) and there is evidence for elevated VEGF-A as a potential predictor of treatment response in major depression (Clark-Raymond et al., 2016) . A majority of studies report higher concentrations of CCL2/MCP-1 in depressed patients compared with controls (Eyre et al., 2016; Kohler et al., 2017) , although some studies have reported the opposite result (Lehto et al., 2010; Myung et al., 2016) . A recent meta-analysis found that antidepressant treatment decreased CCL2/MCP-1 (Kohler et al., 2018) . Higher levels of CCL3/MIP-1α are found in depressed patients compared with controls (Leighton et al., 2018; Merendino et al., 2004) and CCL3/MIP-1α has been suggested as I. Sundberg, et al. Psychoneuroendocrinology xxx (xxxx) xxxx a marker of oxidative stress in depression (Oglodek, 2018) . The relationship between inflammation and depression is influenced by gender and generally more pronounced in females (Birur et al., 2017) .
In the subgroup analysis of female patients in this study, additional associations between daytime melatonin and inflammatory markers IL-8, CD5, CD6 and IL-10RB were identified. These associations may be linked to physiological reactions to oxidative stress as CCL2/MCP-1 is produced in response to oxidative stress (Deshmane et al., 2009 ). Melatonin appears to counteract oxidative stress and reduce levels of CCL2/MCP-1 in animal and cell models (Brazao et al., 2015; Wang et al., 2013) . Furthermore, treatment with melatonin in rats subjected to strenuous exercise resulted in higher levels of VEGF-A, whereas muscular oxidative stress and inflammation were reduced (Borges Lda et al., 2015) .
As far as we know, a link between the lymphocyte marker CD5 and melatonin has not previously been described. The association was strongest for melatonin at 11:00 but also present with post-prandial melatonin before correction for multiple testing. CD5 are receptors present on the surface of T cells, but also exist on a subset of B cells and as soluble receptors circulating in serum (Calvo et al., 1999; Domingues et al., 2016; Sarrias et al., 2004; Sigal, 2012) . The CD5 receptor is an important regulator of lymphocyte selection and immune tolerance (Raman, 2002) . Increased expression of CD5 on either T cells or B cells seems to protect against autoimmunity (Dalloul, 2009) and experimental studies have shown better survival in sepsis models when soluble CD5 has been injected into recipient rats (Sarrias et al., 2007; Vera et al., 2009) . Elevated levels of soluble CD5 are linked to aging (Paltsev et al., 2016) , sepsis (Aibar et al., 2015) and primary Sjögren's syndrome (Ramos-Casals et al., 2001) . In one study, reduced CD5 surface expression on transitional B cells was associated with severe depression and normalized exclusively in clinical responders, possibly indicating a B cell-dependent process in the pathogenesis of depression (Ahmetspahic et al., 2018) . Further investigation of this marker in the context of psychiatric disease is motivated. I. Sundberg, et al. Psychoneuroendocrinology xxx (xxxx) xxxx The gut is a possible source of daytime melatonin. Locally, melatonin in the gut can be 400-fold higher than levels released by the pineal gland, being highest after food intake (Bubenik, 2002) . In a previous study we reported a relationship between post-prandial melatonin levels and gastrointestinal symptoms in the same cohort of patients (Soderquist et al., 2018) . One possible underlying mechanism explaining the association between inflammatory markers and melatonin in this study could be related to intestinal permeability (Martin-Subero et al., 2016) . In this study, daytime melatonin and LBP are not correlated with each other but both have independent correlations with VEGF-A and CCL3/MIP-1α. We could not confirm associations between LBP and BMI shown previously in patients with metabolic syndrome (Sun et al., 2010) . The young adults in this study are generally lean and somatically healthy and longitudinal studies may provide interesting insight in understanding the trajectory and interplay between these factors.
Postprandial melatonin may also contribute to glycemic control. Several studies have shown that individuals with poor glycemic control have higher serum levels of VEGF, CCL2/MCP-1 and CCL3/MIP-1α (Chiarelli et al., 2002; Murphy et al., 2015; Zhang et al., 2018) . In this study, we also noted a positive association between VEGF-A, CCL2/ MCP-1 and CCL3/MIP-1α and BMI: BMI vs VEGF-A (rho 0.247, p = 0.011), BMI vs CCL2/MCP-1 (rho 0.309, p = 0.001) and BMI vs CCL3/MIP-1α (rho 0.216, p = 0.028). In this regard, it can be noted that melatonin has emerged as a hormone important for glucose regulation (Mayo et al., 2018) . A potential relationship between daytime postprandial levels of melatonin and insulin resistance merits further exploration.
Strengths of this study include the measurement of selected cytokines using a separate method to validate the findings. Also, confirmation of inflammatory markers previously found related to psychiatric disorders provides support for the validity of the findings and against type 1 errors. The study approach maximizes the power of the dataset by examining the range of biological variation within the whole population. The relationships between diagnosis and the biological variation are explored post hoc analysis. Our data supports the hypothesis that distinct putative pathoaetiological drivers with respect to inflammation exist and that they may be more or less prevalent within different diagnostic categories. The data, however, also supports the rationale for analyzing the whole population: that underlying biological processes seem to be both diverse within each DSM psychiatric disorder and transdiagnostic.
This study has several limitations. First, blood sampling for inflammatory markers was performed during office hours the day after saliva sampling, but not on a fixed time. Secondly, while the analyses in this study are adjusted for sex, BMI, antidepressant medication and use of oral contraceptives, complete data were not available for other lifestyle factors, such as exercise, alcohol use and smoking, all of which may influence levels of inflammatory markers (Vogelzangs et al., 2016) . Thirdly, the limited amount of saliva did not allow for serial dilutions for concentrations above 50 ng/L. Fourthly, the small sample size may have limited the power of this study to identify the full extent of the relationship between inflammatory markers and melatonin levels. Finally, the cross-sectional design of this study cannot provide information on the causal relationship between melatonin and inflammation over the course of disease.
In conclusion, this study demonstrated, in a psychiatric population, an association between daytime melatonin and several inflammatory markers that have previously been associated with psychiatric disorders. Evening levels of melatonin were not associated with inflammatory markers in this study. Furthermore, we saw a relationship between anxiety disorders, postprandial melatonin levels and VEGF-A and CCL3/MIP-1α. In contrast, CCL2/MCP-1 was negatively associated with depression but not anxiety disorders. These findings may have implications for understanding melatonin in the context of oxidative stress, metabolic dysregulation and inflammation and potentially have relevance in identifying biological mechanisms of psychiatric disease.
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